8-K: Precigen Announces First Quarter 2025 Financial Results and Provides Business Update on PRGN-2012

Precigen reports its Q1 2025 financial results, highlighting progress with PRGN-2012, a potential treatment for Recurrent Respiratory Papillomatosis (RRP), and anticipates a commercial launch in 2025.

Summary

• Precigen announced its first quarter 2025 financial results and provided business updates.
• The company's Biologics License Application (BLA) for PRGN-2012 is under priority review by the FDA, with a PDUFA target action date of August 27, 2025.
• PRGN-2012 has the potential to be the first FDA-approved therapeutic for RRP, a rare chronic disease affecting approximately 27,000 adults in the US and over 125,000 worldwide.
• The company's cash, cash equivalents, and investments totaled $81.0 million as of March 31, 2025, expected to fund operations into 2026.
• First quarter revenues increased by $0.3 million, or 26%, compared to the same period in 2024, primarily due to increased volume of products sold and services rendered at Exemplar.
• Research and development expenses decreased by $3.8 million, or 27%, compared to the first quarter of 2024.
• SG&A expenses increased by $2.2 million, or 22%, compared to the same period in 2024, primarily associated with PRGN-2012 commercial readiness.
• Net loss was $54.2 million, or $(0.18) per basic and diluted share, compared to a net loss of $23.7 million, or $(0.10) per basic and diluted share, in the first quarter of 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress of PRGN-2012 towards potential approval and commercialization, but tempered by the increased net loss in the first quarter.

Positives

• PRGN-2012 has Breakthrough Therapy Designation, Orphan Drug Designation, and an accelerated approval pathway from the FDA.
• The pivotal study of PRGN-2012 met its primary safety and efficacy endpoints.
• The company is advancing its commercial and manufacturing readiness campaign in anticipation of a potential launch in 2025.
• Revenues increased by 26% compared to the same period last year.
• Research and development expenses decreased by 27% compared to the same period last year.

Negatives

• Net loss increased to $54.2 million, or $(0.18) per share, compared to $23.7 million, or $(0.10) per share, in the first quarter of 2024.
• The change in the fair value of warrant liabilities of $32.5 million negatively impacted earnings per share.

Risks

• The FDA may not approve PRGN-2012.
• The company's cash runway is dependent on the potential commercial launch of PRGN-2012.
• The company's forward-looking statements are subject to risks and uncertainties, as detailed in their SEC filings.

Future Outlook

The company anticipates a potential commercial launch of PRGN-2012 in 2025 and expects its cash runway to extend into 2026.

Management Comments

• Helen Sabzevari, PhD, President and CEO of Precigen, stated that they are extremely pleased with the progress of the PRGN-2012 program and its immense potential for RRP patients.
• Harry Thomasian Jr., CFO of Precigen, reiterated that their cash runway is expected to take them into 2026, without consideration of product-related revenue from the potential commercial launch of PRGN-2012 later this year.

Industry Context

The announcement highlights Precigen's focus on gene and cell therapies, particularly in the area of rare diseases like RRP, where there is a significant unmet need for effective treatments. The potential approval of PRGN-2012 would position Precigen as a leader in this space.

Comparison to Industry Standards

• The 51% complete response rate in the PRGN-2012 pivotal study is a strong result compared to existing treatments for RRP, which primarily focus on surgical removal of papillomas.
• Companies like GenVec (acquired by Intrexon, now Precigen) have previously explored gene therapy approaches for HPV-related diseases, but PRGN-2012 appears to be further along in development and closer to potential commercialization.
• The estimated market opportunity of 27,000 adult patients in the US and over 125,000 worldwide suggests a significant commercial potential for PRGN-2012 if approved.

Stakeholder Impact

• Shareholders may be impacted by the potential approval and commercial success of PRGN-2012.
• Patients with RRP could benefit from a new treatment option if PRGN-2012 is approved.
• Employees are involved in the commercial readiness campaign for PRGN-2012.

Next Steps

• The company will continue to work with the FDA during the priority review of the BLA for PRGN-2012.
• Precigen will host the 2025 International RRP Awareness Day on June 11.
• The company will continue to advance its commercial and manufacturing readiness campaign in anticipation of a potential launch in 2025.
• Patient enrollment continues to advance in the confirmatory clinical trial of PRGN-2012.

Key Dates

Keywords

PRGN-2012, RRP, AdenoVerse, Gene Therapy, Financial Results, Precigen, Biopharmaceutical